Related Experiment Videos
Pharmacologic management of refractory depression
S B Patten1, D A Lupin, S A Boucher
1Department of Community Health Sciences, Faculty of Medicine, University of Calgary, AB.
Summary
Current pharmacologic treatments for refractory depression lack strong evidence. Methodologically sound studies do not support commonly recommended strategies for managing treatment-resistant depression.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Refractory depression poses a significant clinical challenge.
- Effective pharmacologic management strategies are crucial for treatment-resistant cases.
Purpose of the Study:
- To critically review published clinical trials on the pharmacologic management of refractory depression.
- To assess the methodological rigor of studies evaluating treatments for treatment-resistant depression.
Main Methods:
- Systematic literature search of MEDLINE (1983-1990) and review article bibliographies.
- Inclusion of only pharmacologic treatment studies, excluding non-pharmacologic interventions.
- Rigorous methodological assessment using adapted McMaster guidelines by two independent reviewers.
Main Results:
- Evidence did not support lithium carbonate, triiodothyronine, or reserpine augmentation for refractory depression.
- Many trials had insufficient statistical power to definitively rule out efficacy.
- One study supported monoamine oxidase inhibitors, but lacked double-blind conditions.
Conclusions:
- Existing recommended pharmacologic strategies for refractory depression are not substantiated by methodologically sound clinical trials.
- Further high-quality research is needed to establish effective treatments for treatment-resistant depression.